Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 157
Healthy volunteers: no

Brief summary:
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.

Detailed description:

Arms:
arm 1: Low dose inhaled orally once daily from the Respimat inhaler arm 2: High dose inhaled orally once daily from the Respimat inhaler arm 3: Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler

Interventions: intervention 1: Olodaterol (BI 1744) intervention 2: Olodaterol (BI 1744) intervention 3: Placebo intervention 4: Olodaterol (BI1744) intervention 5: Olodaterol (BI 1744) placebo
Intervention descriptions: intervention 1: Comparison of low and high dose on exercise endurance time in COPD patients intervention 2: Comparison of low and high dose on exercise endurance time in COPD patients intervention 3: Comparison of low and high dose and placebo on exercise endurance time in COPD patients intervention 4: Comparison of low and high dose on exercise endurance time in COPD patients intervention 5: Placebo that represents olodaterol

Protocol document: